From Lab To Launch: Cutting Time In Pharmaceutical Development

By Stefan Randl, Chief Scientific Officer

The pressure to accelerate drug development continues to intensify as rising costs, shortened periods of market exclusivity, and growing patient demand push companies to bring therapies to market faster. While rapid approvals during the COVID-19 era demonstrated what is possible, sustainable acceleration requires rethinking how development is approached across the entire value chain.

Artificial intelligence is emerging as a powerful tool for improving candidate selection, optimizing clinical trial design, and accelerating chemistry, manufacturing, and controls (CMC) activities. At the same time, Quality by Design (QbD), advanced process modeling, and data-driven manufacturing strategies are helping teams reduce development cycles while maintaining quality and regulatory compliance.

Yet technology alone is not enough. Effective communication, seamless data sharing, and close collaboration between pharmaceutical companies, CDMOs, and regulatory stakeholders remain essential to keeping programs on track. Explore how a combination of digital innovation, scientific rigor, and strong partnerships is helping the industry shorten timelines and deliver medicines to patients sooner.